TP53 and B-cell non-Hodgkin lymphoma: Intriguingly, when ASCT was further combined with CAR19/22 T-cell sequential infusion, superior response and survival were obtained in TP53-disrupted B-cell lymphoma, even in patients with a SD/PD before transplantation, for whom, as indicated in the SCHOLAR-1 study, ASCT alone can hardly provide durable disease control1.